Michael P. Cooreman
Chief Tech/Sci/R&D Officer bij INVENTIVA
Vermogen: 53 784 $ op 31-03-2024
Profiel
Michael P.
Cooreman is currently the Chief Medical Officer at Inventiva SA since 2020.
Prior to this, he was the Vice President-Science & Medicine at Ferring Pharmaceuticals, Inc. from 2017 to 2020 and the Chief Medical Officer at ImmusanT, Inc. from 2015 to 2017.
He holds a doctorate degree from Heinrich-Heine-Universität Düsseldorf and Université Catholique de Louvain.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
INVENTIVA SA
0.03% | 01-03-2024 | 15 000 ( 0.03% ) | 53 784 $ | 31-03-2024 |
Actieve functies van Michael P. Cooreman
| Bedrijven | Functie | Begin |
|---|---|---|
| INVENTIVA | Chief Tech/Sci/R&D Officer | 01-11-2020 |
Eerdere bekende functies van Michael P. Cooreman
| Bedrijven | Functie | Einde |
|---|---|---|
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Corporate Officer/Principal | 01-01-2020 |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01-01-2017 |
Opleiding van Michael P. Cooreman
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
| Université Catholique de Louvain | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INVENTIVA | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
